We are very excited to have Dr. Widemann as our guest lecturer!!
Please join us to learn more about the efforts in cures and treatments for childhood cancers!!

Dr. Brigitte C. Widemann, M. D. 
Chief Pediatric Oncology Branch
Senior Investigator
Head, Pharmacology and Experimental Therapeutics Section
Special Advisor to the NCI Director for Childhood Cancer

Dr. Brigitte Widemann is a pediatric oncologist with the primary interest of developing effective therapies for children and adults with genetic tumor predisposition syndromes, such as neurofibromatosis type 1 (NF1), and rare solid tumors through innovative clinical trial design. Dr. Widemann currently serves as the head of the Pharmacology & Experimental Therapeutics Section and as Chief of NCI’s Pediatric Oncology Branch. Dr. Widemann is also a medical advisor to a new NCI initiative to Advance RASopathy Therapies (ART) and serves as Special Advisor on Childhood Cancer to the NCI Director.  

Anticancer drug discovery and development are moving towards a more rational and targeted approach. The application of new molecularly targeted agents to the treatment of childhood cancers and neurofibromatosis type 1 (NF1) is a research objective of the Pharmacology & Experimental Therapeutics Section (PETS). In addition to studying the pharmacology, pharmacokinetics, pharmacodynamics, and toxicities of these novel agents, it is also a goal of the PETS to evaluate novel clinical trial designs and trial endpoints, which may be more applicable for molecularly targeted agents.